FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Nashington, | D.C. 20549 |
|-------------|------------|
|-------------|------------|

| CTATEMENT | \sim | CHARICEC | INI DENIE | | OWNIEDCIII | _ |
|-----------|--------|----------|-----------|--------|------------|---|
| STATEMENT | OF. | CHANGES | IIN BEINE | FICIAL | OWNERSHI | Р |
| | | | | | | - |

| OMB APPROVAL | | | | | | | | | |
|--------------------------|-------|--|--|--|--|--|--|--|--|
| OMB Number: 3235-0287 | | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours per response | : 0.5 | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* Elston George | | | | Eye | 2. Issuer Name and Ticker or Trading Symbol EyePoint Pharmaceuticals, Inc. [EYPT] | | | | | | (Ch | eck all appli Directo Officer | cable) | 10% Owner live title Other (specify | | | |
|--|--|------------|---------------------------------------|---|--|--|--------------------------------------|---------------------|--|-------|---|---|---|--|--|---|------------|
| (Last) (First) (Middle) C/O EYEPOINT PHARMACEUTICALS, INC. | | | | 3. Date of Earliest Transaction (Month/Day/Year) 05/25/2023 | | | | | | | below) | hief Finaı | ncial | below) Officer | | | |
| 480 PLEASANT STREET | | | | 4. If a | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | Line | , | | | | | |
| (Street) WATER | ГОWN M | A | 02472 | | | | | | | | | Form f | Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | |
| (City) (State) (Zip) | | | | Ru | Rule 10b5-1(c) Transaction Indication | | | | | | | | | | | | |
| | | | | | | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | | | | |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transar Date (Month/Da | | | | Execution Da | | Date, | Transaction Disposed Code (Instr. 5) | | ities Acquir d Of (D) (In: | | Benefici | es ally Following | Form (D) o | : Direct r Indirect str. 4) | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | | Code | V Ar | nount | ount (A) or (D) | | Transac | Transaction(s) (Instr. 3 and 4) | | | (Instr. 4) |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | |
| Derivative Conversion Date Execution Date, T Security or Exercise (Month/Day/Year) if any C | | | ransaction of Code (Instr. Derivative | | | Expiration Date (Month/Day/Year) Amor Secu Unde Deriv | | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4) | ily | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expira Date | ation | Title | Amount or Number of Shares | | | | | |
| Stock Option (Right to Buy) | \$5.93 | 05/25/2023 | | A | | 45,000 | | (1) | 05/24/ | 2033 | Common Stock | 45,000 | \$0.00 | 45,000 | | D | |
| Restricted Stock Units | \$0.00 | 05/25/2023 | | A | | 22,500 | | (2) | (2 |) | Common Stock | 22,500 | \$0.00 | 22,500 | | D | |

Explanation of Responses:

- 1. The option to purchase will vest and become exercisable as follows: 25% at May 25th, 2024 and the remainder ratably, on a monthly basis, over the remaining three years.
- $2. \ The \ restricted \ stock \ units \ will \ vest \ in \ three \ ratable \ annual \ installments \ beginning \ May \ 25, \ 2024.$

Remarks:

/s/ Ron Honig, Attorney-in-Fact 05/30/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.